Cyclooxygenase-2 inhibitors and other NSAIDs in urology: Current peril or future promise?

Urology

Volumn 68, Issue 5, 2006, Pages 917-923

  Pruthi, Raj S ^a   Kouba, Erik ^a   Carson III, Culley C ^a   Wallen, Eric M ^a  

^a UNIVERSITY OF NORTH CAROLINA   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ACETYLSALICYLIC ACID; CELECOXIB; CYCLOOXYGENASE 1; CYCLOOXYGENASE 2; CYCLOOXYGENASE 2 INHIBITOR; DOCETAXEL; FINASTERIDE; IBUPROFEN; NONSTEROID ANTIINFLAMMATORY AGENT; PLACEBO; PROSTACYCLIN; ROFECOXIB; VALDECOXIB;

ADENOMATOUS POLYP; ANALGESIC ACTIVITY; ANTIINFLAMMATORY ACTIVITY; ATHEROGENESIS; BLADDER CANCER; BLEEDING; BONE METASTASIS; BREAST CANCER; CANCER HORMONE THERAPY; CANCER RISK; CARCINOGENESIS; CARDIOTOXICITY; CARDIOVASCULAR DISEASE; CARDIOVASCULAR RISK; CLINICAL TRIAL; COLON CANCER; CYSTITIS; DIET SUPPLEMENTATION; DRUG EFFICACY; DRUG MARKETING; DRUG SAFETY; DRUG SELECTIVITY; ENZYME ACTIVITY; GASTROINTESTINAL SYMPTOM; HEMOSTASIS; HUMAN; KIDNEY BLOOD FLOW; KIDNEY CARCINOMA; KIDNEY COLIC; NONHUMAN; PAIN; PRIORITY JOURNAL; PROSTATE CANCER; PROSTATE HYPERTROPHY; PROTEIN EXPRESSION; PROTEIN FUNCTION; RENOVASCULAR DISEASE; REVIEW; RISK ASSESSMENT; SIDE EFFECT; SKIN TOXICITY; THROMBOCYTE AGGREGATION INHIBITION; THROMBOSIS; TRANSITIONAL CELL CARCINOMA; VASOCONSTRICTION;

ANTI-INFLAMMATORY AGENTS, NON-STEROIDAL; CARDIOVASCULAR DISEASES; CYCLOOXYGENASE 2; CYCLOOXYGENASE 2 INHIBITORS; FORECASTING; HUMANS; UROLOGIC DISEASES;

EID: 33751005826     PISSN: 00904295     EISSN: 15279995     Source Type: Journal    
DOI: 10.1016/j.urology.2006.06.013     Document Type: Review

References (50)

1. Vane J.R. Inhibition of prostaglandin synthesis as a mechanism of action for aspirin-like drugs. Nat New Biol 231 (1971) 232-235
2. Koki A.T., and Masferrer J.L. Celecoxib: a specific COX-2 inhibitor with anticancer properties. Cancer Control 9 2 suppl (2002) 28-35
3. Pruthi R.S., Derksen J.E., and Gaston K. Cyclooxygenase-2 as a potential target in the prevention and treatment of genitourinary tumors: a review. J Urol 169 (2003) 2352-2359
4. de Leval X., Hanson J., David J.L., et al. New developments on thromboxane and prostacyclin modulators part II: prostacyclin modulators. Curr Med Chem 11 (2004) 1243-1252
5. Dogne J.M., de Leval X., Hanson J., et al. New developments on thromboxane and prostacyclin modulators-part I: thromboxane modulators. Curr Med Chem 11 (2004) 1223-1241
6. Kimmel S.E., Berlin J.A., Reilly M., et al. Patients exposed to rofecoxib and celecoxib have different odds of nonfatal myocardial infarction. Ann Intern Med 142 (2005) 157-164
7. Bresalier R.S., Sandler R.S., Quan H., et al., Adenomatous Polyp Prevention on Vioxx (APPROVe) Trial Investigators. Cardiovascular events associated with rofecoxib in a colorectal adenoma chemoprevention trial. N Engl J Med 352 (2005) 1092-1102
8. Solomon S.D., McMurray J.J., Pfeffer M.A., et al., Adenoma Prevention with Celecoxib (APC) Study Investigators. Cardiovascular risk associated with celecoxib in a clinical trial for colorectal adenoma prevention. N Engl J Med 352 (2005) 1071-1080
9. FDA Public Health Advisory: FDA announces important changes and additional warnings for COX-2 selective and non-selective non-steroidal anti-inflammatory drugs (NSAIDs). Available at: www.fda.gov/cder/drug/advisory/COX2.htm. Accessed May 15, 2005.
10. Lecci A., Birder L.A., Meini S., et al. Pharmacological evaluation of the role of cyclooxygenase isoenzymes on the micturition reflex following experimental cystitis in rats. Br J Pharmacol 130 (2000) 331-338
11. Yotsuyanagi S., Yokoyama O., Komatsu K., et al. Role of cyclooxygenase-2 in the development of bladder overactivity after cerebral infarction in the rat. J Urol 174 (2005) 365-369
12. Erdogru T., Celik-Ozenci C., Seval Y., et al. The restorative effect of a selective cyclooxygenase-2 inhibitor on urothelial cell-cell interactions after partial bladder outlet obstruction in rats. BJU Int 95 (2005) 664-669
13. Pontari M.A. Inflammation and anti-inflammatory therapy in chronic prostatitis. Urology 60 (2002) 29-32
14. Wang W., Bergh A., and Damber J.E. Chronic inflammation in benign prostate hyperplasia is associated with focal upregulation of cyclooxygenase-2, Bcl-2, and cell proliferation in the glandular epithelium. Prostate 61 (2004) 60-72
15. Lee L.M., Pan C.C., Cheng C.J., et al. Expression of cyclooxygenase-2 in prostate adenocarcinoma and benign prostatic hyperplasia. Anticancer Res 21 suppl 2B (2001) 1291-1294
16. Minnery C.H., and Getzenberg R.H. Benign prostatic hyperplasia cell line viability and modulation of jm-27 by doxazosin and ibuprofen. J Urol 174 (2005) 375-379
17. Di Silverio F., Bosman C., Salvatori M., et al. Combination therapy with rofecoxib and finasteride in the treatment of men with lower urinary tract symptoms (LUTS) and benign prostatic hyperplasia (BPH). Eur Urol 47 (2005) 72-78
18. Roehrborn C.G., Kaplan S.A., Noble W.D., et al. The impact of acute or chronic inflammation in baseline biopsy on the risk of clinical progression of BPH: results of the MTOP study. (abstract). J Urol 173 (2005) 204
19. Jerde T.J., Calamon-Dixon J.L., Bjorling D.E., et al. Celecoxib inhibits ureteral contractility and prostanoid release. Urology 65 (2005) 185-190
20. Labrecque M., Dostaler L.P., Rousselle R., et al. Efficacy of nonsteroidal anti-inflammatory drugs in the treatment of acute renal colic: a meta-analysis. Arch Intern Med 154 (1994) 1381-1387
21. Katz W.A. Cyclooxygenase-2-selective inhibitors in the management of acute and perioperative pain. Cleve Clin J Med 69 suppl 1 (2002) SI65-SI75
22. Barton S.F., Langeland F.F., Snabes M.C., et al. Efficacy and safety of intravenous parecoxib sodium in relieving acute postoperative pain following gynecologic laparotomy surgery. Anesthesiology 97 (2002) 306-314
23. Koizuka S., Saito S., Obata H., et al. Oral etodolac, a COX-2 inhibitor, reduces postoperative pain immediately after fast-track cardiac surgery. J Anesth 18 (2004) 9-13
24. Sinatra R.S., Torres J., and Bustos A.M. Pain management after major orthopaedic surgery: current strategies and new concepts. J Am Acad Orthop Surg 10 (2002) 117-129
25. See W.A., Fuller J.R., and Toner M.L. An outcome study of patient-controlled morphine analgesia, with or without ketorolac, following radical retropubic prostatectomy. J Urol 154 (1995) 1429-1432
26. Cabrera M.C., Schmied S., Derderian T., et al. Efficacy of oral rofecoxib versus intravenous ketoprofen as an adjuvant to PCA morphine after urologic surgery. Acta Anaesthesiol Scand 48 (2004) 1190-1193
27. Stefaniak H., Wallen E., and Pruthi R.S. The use of the COX-2 inhibitor celecoxib to reduce perioperative pain associated with radical retropubic prostatectomy (RRP) (2005) Presented at the American Urological Association, Southeastern Section, March 3, Charleston, South Carolina
28. Hussain T., Gupta S., Adhami V.M., et al. Green tea constituent epigallocatechin-3-gallate selectively inhibits COX-2 without affecting COX-1 expression in human prostate carcinoma cells. Int J Cancer 113 (2005) 660-669
29. Goldmann W.H., Sharma A.L., Currier S.J., et al. Saw palmetto berry extract inhibits cell growth and COX-2 expression in prostatic cancer cells. Cell Biol Int 25 (2001) 1117-1124
30. Kim H.Y., Yu R., Kim J.S., et al. Antiproliferative crude soy saponin extract modulates the expression of IkappaBalpha, protein kinase C, and cyclooxygenase-2 in human colon cancer cells. Cancer Lett 210 (2004) 1-6
31. Pham H., Banerjee T., and Ziboh V.A. Suppression of cyclooxygenase-2 overexpression by 15S-hydroxyeicosatrienoic acid in androgen-dependent prostatic adenocarcinoma cells. Int J Cancer 111 (2004) 192-197
32. Baines A., Taylor-Parker M., Goulet A.C., et al. Selenomethionine inhibits growth and suppresses cyclooxygenase-2 (COX-2) protein expression in human colon cancer cell lines. Cancer Biol Ther 1 (2002) 370-374
33. Mahmud S., Franco E., and Aprikian A. Prostate cancer and use of nonsteroidal anti-inflammatory drugs: systematic review and meta-analysis. Br J Cancer 90 (2004) 93-99
34. Norrish A.E., Jackson R.T., and McRae C.U. Non-steroidal anti-inflammatory drugs and prostate cancer progression. Int J Cancer 77 (1998) 511-516
35. Jacobs E.J., Rodriguez C., Mondul A.M., et al. A large cohort study of aspirin and other nonsteroidal anti-inflammatory drugs and prostate cancer incidence. J Natl Cancer Inst 97 (2005) 975-980
36. Zha S., Gage W.R., Sauvageot J., et al. Cyclooxygenase-2 is up-regulated in proliferative inflammatory atrophy of the prostate, but not in prostate carcinoma. Cancer Res 61 (2001) 8617-8623
37. Liu X.H., Kirschenbaum A., Yao S., et al. Inhibition of cyclooxygenase-2 suppresses angiogenesis and the growth of prostate cancer in vivo. J Urol 164 (2000) 820-827
38. Gupta S., Adhami V.M., Subbarayan M., et al. Suppression of prostate carcinogenesis by dietary supplementation of celecoxib in transgenic adenocarcinoma of the mouse prostate model. Cancer Res 64 (2004) 3334-3343
39. Pruthi R.S., and Derksen J.E. A phase II trial of celecoxib in PSA-recurrent prostate cancer after definitive radiation therapy or radical prostatectomy. Clin Cancer Res 12 (2006) 2172-2177
40. Dandekar D.S., and Lokeshwar B.L. Inhibition of cyclooxygenase (COX)-2 expression by Tet-inducible COX-2 antisense cDNA in hormone-refractory prostate cancer significantly slows tumor growth and improves efficacy of chemotherapeutic drugs. Clin Cancer Res 10 (2004) 8037-8047
41. Wen B., Deutsch E., Eschwege P., et al. Cyclooxygenase-2 inhibitor NS398 enhances antitumor effect of irradiation on hormone refractory human prostate carcinoma cells. J Urol 170 (2003) 2036-2039
42. Sabino M.A., Ghilardi J.R., Jongen J.L., et al. Simultaneous reduction in cancer pain, bone destruction, and tumor growth by selective inhibition of cyclooxygenase-2. Cancer Res 62 (2002) 7343-7349
43. Pruthi R.S., Gaston K., Derksen J.E., et al. Rationale for the use of COX-2 inhibitors in bladder cancer. Urology 64 (2004) 637-642
44. Rao K.V., Detrisac C.J., Steele V.E., et al. Differential activity of aspirin, ketoprofen and sulindac as cancer chemopreventive agents in the mouse urinary bladder. Carcinogenesis 17 (1996) 1435-1438
45. Grubbs C.J., Lubet R.A., Koki A.T., et al. Celecoxib inhibits N-butyl-N-(4-hydroxybutyl)-nitrosamine-induced urinary bladder cancers in male B6D2F1 mice and female Fischer-344 rats. Cancer Res 60 (2000) 5599-5604
46. Mohammed S.I., Bennett P.F., Craig B.A., et al. Effects of the cyclooxygenase inhibitor, piroxicam, on tumor response, apoptosis, and angiogenesis in a canine model of human invasive urinary bladder cancer. Cancer Res 62 (2002) 356-358
47. Shariat S.F., Matsumoto K., Kim J., et al. Correlation of cyclooxygenase-2 expression with molecular markers, pathological features and clinical outcome of transitional cell carcinoma of the bladder. J Urol 170 (2003) 985-989
48. Badawi A.F., Habib S.L., Mohammed M.A., et al. Influence of cigarette smoking on prostaglandin synthesis and cyclooxygenase-2 gene expression in human urinary bladder cancer. Cancer Invest 20 (2002) 651-656
49. Fujioka T., Hasegawa M., Ogiu K., et al. Antitumor effects of angiogenesis inhibitor fumagillol (TNP-470) against murine renal cell carcinoma. J Urol 155 (1996) 1775-1779
50. Barna B.P., Thomassen M.J., Sergi J., et al. Immunologic changes in renal cell carcinoma patients receiving gamma interferon. Oncology 48 (1991) 464-470